NCT05133050View on ClinicalTrials.gov

Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

NANot yet recruitingINTERVENTIONAL

Enrollment

510

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions

Alport Syndrome

Interventions

DRUG

Ramipril

We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.

Trial Locations (1)

Unknown

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT05133050 - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants | Biotech Hunter | Biotech Hunter